-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16

Benzinga·08/12/2026 16:04:10
Listen to the news
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.